Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Plasma lipidomic signature of rectal adenocarcinoma reveals Potential Biomarkers

Full text
Author(s):
Fernandes Messias, Marcia Cristina [1] ; Mecatti, Giovana Colozza [1] ; Figueiredo Angolini, Celio Fernando [2] ; Eberlin, Marcos Nogueira [2] ; Credidio, Laura [3] ; Real Martinez, Carlos Augusto [3] ; Rodrigues Coy, Claudio Saddy [3] ; Carvalho, Patricia de Oliveira [1]
Total Authors: 8
Affiliation:
[1] Sao Francisco Univ USF, Lab Multidisciplinary Res, Braganca Paulista, SP - Brazil
[2] Univ Estadual Campinas, UNICAMP, Inst Chem, Campinas, SP - Brazil
[3] Univ Estadual Campinas, UNICAMP, Dept Surg, Campinas, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: FRONTIERS IN ONCOLOGY; v. 7, JAN 8 2018.
Web of Science Citations: 6
Abstract

Background: Rectal adenocarcinoma (RAC) is a common malignant tumor of the digestive tract and survival is highly dependent upon stage of disease at diagnosis. Lipidomic strategy can be used to identify potential biomarkers for establishing early diagnosis or therapeutic programs for RAC. Objective: To evaluate the lipoperoxidation biomarkers and lipidomic signature in the plasma of patients with RAC (n = 23) and healthy controls (n = 18). Methods: Lipoperoxidation was evaluated based on malondialdehyde (MDA) and F-2-isoprostane levels and the lipidomic profile obtained by gas chromatography and high resolution mass spectrometry (ESI-q-TOF) associated with a multivariate statistical technique. Results: The most abundant ions identified in the RAC patients were those of protonated phosphatidylcholine and phosphatidylethanolamine. It was found that a lisophosphati-dylcholine (LPC) plasmalogen containing palmitoleic acid {[}LPC (P-16:1)], with highest variable importance projection score, showed a tendency to be lower in the cancer patients. A reduction of n - 3 polyunsaturated fatty acids was observed in the plasma of these patients. MDA levels were higher in patients with advanced cancer (stages III/IV) than in the early stages groups and the healthy group (p < 0.05). No differences in F-2-isoprostane levels were observed among these groups. Conclusion: This study shows that the reduction in plasma levels of LPC plasmalogens associated with an increase in MDA levels may indicate increased oxidative stress in these patients and identify the metabolite LPC (P-16:1) as a putatively novel lipid signature for RAC. (AU)

FAPESP's process: 16/11905-2 - Lipidomic analysis of cancer patients blood in the search for possible circulatory biomarkers
Grantee:Patrícia de Oliveira Carvalho
Support Opportunities: Regular Research Grants